Okay, yes - there are momentum players piling in on this. Nothing new about that. There are shorts being squeezed, and new longs who think there's value right at these levels. The fact is that pima (ACAD) will either be bought out (at the right price), or given enough time, and approval for ADP, this could easily make it $50. It's about as close to a pure play in the world of biotech as you're going to find.